TITLE

BIOTECHNOLOGY: ImaRx shifts away from microbubble development

PUB. DATE
February 2008
SOURCE
Inside Tucson Business;2/4/2008, Vol. 17 Issue 34, p10
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the plan of ImaRx Therapeutics Inc. to shift its business focus to market urokinase drug in Arizona. Urokinase is a commercially available drug approved by the Food and Drug Administration for dissolving clots in patients with acute massive pulmonary embolism or blood clot in the lungs. The switch of its business focus is part of its agreement with Microbix Biosystems Inc., a developer of urokinase, to commercially develop the product.
ACCESSION #
29328937

 

Related Articles

  • ImaRx Shares Spike on Sale of Urokinase to Microbix. Turner, Tiffany // BioWorld Today;5/8/2008, Vol. 19 Issue 90, p1 

    The article reports on the decision of Microbix Biosystems to acquire urokinase inventory and related assets from ImaRx Therapeutics Inc. The deal increased the shares of ImaRx Therapeutics to 155 percent or 51 cents and it also changed the company's product focus. Under the acquisition deal,...

  • ImaRx, Microbix Cancel $17M Urokinase Sale.  // BioWorld Today;6/12/2008, Vol. 19 Issue 114, p2 

    The article reports on the cancellation of a $17 million deal in which ImaRx Therapeutics Inc. will sell its urokinase program to Microbix Biosystems Inc. The cancellation has left ImaRx cutting staff and evaluating alternative strategies to maximize shareholder value, which brings into play the...

  • ImaRx deal falls through, employees laid off.  // Inside Tucson Business;6/16/2008, Vol. 18 Issue 2, p4 

    The article focuses on the decision of Arizona-based ImaRx Therapeutics Inc. to lay off most of its 20-employee workforce. A biopharmaceutical company, ImaRx Therapeutics explains that the move followed its prior decision to terminate an agreement with Toronto-based Microbix Biosystems Inc. and...

  • ImaRx changes courses, back to microbubbles.  // Inside Tucson Business;5/12/2008, Vol. 17 Issue 49, p4 

    The article reports on the move of ImaRx Therapeutics Inc. to sell its anticlotting drug urokinase inventory to Microbix Biosystems Inc. in Toronto, Ontario for $17 million. The company's decision has been the result of its plan to shift its business focus from developing proprietary microbubble...

  • ImaRx Sells Urokinase to Microbix.  // Bioworld Week;5/12/2008, Vol. 16 Issue 19, p1 

    The article reports on the acquisition of ImaRx Therapeutics Inc.'s urokinase inventory and related assets by Microbix Biosystems Inc. for $17 million in cash in the U.S. Microbix bought urokinase for an up-front payment of $12 million and an additional $5 million upon achievement of an...

  • ImaRx Changes Direction, Seeks Alternatives for Stroke Program. Boggs, Jennifer // BioWorld Today;1/31/2008, Vol. 19 Issue 21, p1 

    The article reports that ImaRx Therapeutics Inc. plans to focus on building the market for urokinase, an approved lot-busting agent initially acquired from Abbott in 2006. The company has been focusing much of its resources developing its microbubbles-plus-ultrasound SonoLysis therapy for...

  • ImaRx switches focus from Sonolysis to urokinase.  // Medical Device Daily;1/31/2008, Vol. 12 Issue 21, p2 

    The article reports on the decision of ImaRx Therapeutics to change its focus from producing Sonolysis to urokinase product. This decision was made after it discontinued its trial on Sonolysis, a therapy using microbubbles and ultrasound to treat ischemic stroke. The company has signed a...

  • MICROBIX REPORTS 104% RISE IN SALES AND PROFITABILITY.  // Biotech Financial Reports;Jul2001, p3 

    Reports on the increase in the earnings of Microbix Biosystems Inc.'s biotechnology business for the first half of fiscal 2001. Statistics of the company's research and development expenditures; Comparison with earnings for the same period in 2000.

  • Financings Roundup.  // BioWorld Today;12/3/2010, Vol. 21 Issue 233, p6 

    The article reports that Microbix Biosystems Inc. in Toronto, Ontario, has formed Crucible International Biotechnologies Corp. which will facilitate the start-up and operation of its joint venture in China and commercialize the Virusmax technology.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics